Foolish bottom line
There’s no denying that Pfizer Inc. (NYSE:PFE) has outperformed its $100 billion peers in the past five years.
Can it continue? Fellow Fool David Williamson recently outlined why the lackluster first quarter didn’t matter for investors, and I couldn’t agree more. Pfizer Inc. (NYSE:PFE)’s pipeline is full of big potential that could justify even higher valuations. I think a focus on pharmaceuticals will allow the company to continue to outperform the market in the next three years and am initiating a CAPScall to track my call.
The article Is the Biggest Pharma Company in the World the Best Investment? originally appeared on Fool.com.
Fool contributor Maxx Chatsko has no position in any stocks mentioned. Check out his personal portfolio, his CAPS page, or follow him on Twitter @BlacknGoldFool to keep up with his writing on energy, bioprocessing, and emerging technologies.The Motley Fool recommends Johnson & Johnson. The Motley Fool owns shares of Johnson & Johnson.
Copyright © 1995 – 2013 The Motley Fool, LLC. All rights reserved. The Motley Fool has a disclosure policy.